Last reviewed · How we verify
Acanya Gel — Competitive Intelligence Brief
phase 3
Topical antibiotic combination
Cutibacterium acnes (bacterial protein synthesis inhibition); benzoyl peroxide acts as an oxidizing antimicrobial
Dermatology
Small molecule
Live · refreshed every 30 min
Target snapshot
Acanya Gel (Acanya Gel) — Padagis LLC. Acanya Gel combines clindamycin (an antibiotic) and benzoyl peroxide (an antimicrobial oxidizing agent) to reduce acne-causing bacteria and decrease sebum production.
Comparator set (6 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Acanya Gel TARGET | Acanya Gel | Padagis LLC | phase 3 | Topical antibiotic combination | Cutibacterium acnes (bacterial protein synthesis inhibition); benzoyl peroxide acts as an oxidizing antimicrobial | |
| Duac Gel | Duac Gel | Stiefel, a GSK Company | marketed | Topical antibiotic combination | Propionibacterium acnes (bacterial target); benzoyl peroxide acts via oxidative mechanism; clindamycin inhibits bacterial protein synthesis | |
| BENZOYL PEROXIDE/ CLINDAMYCIN | BENZOYL PEROXIDE/ CLINDAMYCIN | Stiefel, a GSK Company | marketed | Topical antibiotic combination | Bacterial ribosome (clindamycin); reactive oxygen species generation (benzoyl peroxide) | |
| Acnatac® Gel left face | Acnatac® Gel left face | GWT-TUD GmbH | marketed | Topical antibiotic combination | Bacterial ribosome (clindamycin); oxidative stress induction (benzoyl peroxide) | |
| Intranasal Mupirocin and Topical Chlorhexidine | Intranasal Mupirocin and Topical Chlorhexidine | University of Maryland, Baltimore | marketed | Topical antibiotic combination | Bacterial isoleucyl-tRNA synthetase (mupirocin); bacterial cell membrane and proteins (chlorhexidine) | |
| Polysporin Ointment | Polysporin Ointment | University of British Columbia | marketed | Topical antibiotic combination | Bacterial cell wall (bacitracin) and bacterial cell membrane (polymyxin B) | |
| Benzoyl peroxide with clindamycin | Benzoyl peroxide with clindamycin | Stiefel, a GSK Company | marketed | Topical antibiotic combination | Bacterial ribosomes (clindamycin); reactive oxygen species generation (benzoyl peroxide) |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Topical antibiotic combination class)
- Stiefel, a GSK Company · 3 drugs in this class
- GlaxoSmithKline · 3 drugs in this class
- GWT-TUD GmbH · 2 drugs in this class
- Sun Pharmaceutical Industries, Inc. · 1 drug in this class
- University Health Network, Toronto · 1 drug in this class
- University of British Columbia · 1 drug in this class
- University of Maryland, Baltimore · 1 drug in this class
- B. Braun Medical SA · 1 drug in this class
- Watson Laboratories, Inc. · 1 drug in this class
- Padagis LLC · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Acanya Gel CI watch — RSS
- Acanya Gel CI watch — Atom
- Acanya Gel CI watch — JSON
- Acanya Gel alone — RSS
- Whole Topical antibiotic combination class — RSS
Cite this brief
Drug Landscape (2026). Acanya Gel — Competitive Intelligence Brief. https://druglandscape.com/ci/acanya-gel. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing